Email: cspc@cspc.cn
Email: cspc@cspc.cn
February 21, 2024
Led by Professor Guo Xiaohui from Peking University First Hospital, the phase III clinical study on monotherapy of type 2 diabetes using DBPR108 (Prusogliptin) tablets demonstrates good glucose-lowering effect and safety. The results have been accepted and published in the Diabetes, Obesity and Metabolism (weblink: http://doi.org/10.1111/dom.15433).
